Dublin, Calif. – April 24, 2019 – Azure Biosystems acqquires Dx BioTech, linking the company with ground-breaking FiberFlowFluidics™ optical fiber flow cytometry technology. The acquisition expands Azure’s portfolio of proteomics-enabling intellectual property to single cell analysis, and keeps Azure positioned as a leading innovator in proteomics instrumentation.
In addition to being bulky and expensive, current commercial flow cytometers are highly sensitive to vibrations, making them costly to maintain and difficult to move. This sensitivity is the result of an “open,” free-space laser and optics architecture—the laser and detection path must remain in perfect alignment or the function of the instrument is greatly impaired. Azure’s newly-acquired optical fiber flow cytometry technology closes this gap, keeping the laser and optical path confined and on target with optical fibers. The result promises to be more robust and rugged flow cytometers that are smaller and even portable, bringing this gold-standard cell and proteomics analysis technique to a much larger number of labs.
Sia Ghazvini, Executive Vice President of Commercial Operations for Azure Biosystems, is also enthusiastic about the recent acquisition, “We look forward to incorporating the Dx BioTech optical fiber flow technology into a rugged, well-differentiated commercial flow cytometer and are excited to continue innovating in the proteomics instrumentation space.”
About Azure Biosystems
Azure Biosystems Inc. is an innovative life science platform company that designs, develops and markets state-of-the-art instruments, including the Ao™ absorbance microplate reader, the cSeries™ imaging platforms and the Sapphire™ Biomolecular Imager. Azure Biosystem’s experienced team has developed 2nd and 3rd generation imaging systems for the life science market, thus applying their technical and market knowledge in creating innovative industry standard-setting platforms.